Compare Regeneron Pharmaceuticals Inc (REGN) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Teladoc Health Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 75.6× Teladoc Health Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Teladoc Health Inc for 39 Days on average.
| REGN | TDOC | |
|---|---|---|
Market Cap | $76.40B | $1.01B |
Volume | 626,381 | 3,622,440 |
Sector | Health | Health |
52-Week High | $852.03 | $9.72 |
52-Week Low | $557.73 | $4.47 |
Typical Hold Time | 107 Days | 39 Days |
Enterprise Value | $71.12B | $1.27B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Teladoc Health (TDOC) trades at $5.54, down 3.99% in the latest session, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with oversold conditions while fundamentals reveal a mixed picture - strong gross margins of 68.97% but persistent net losses. Recent management changes and legal investigations add uncertainty, though the company maintains solid cash flow from operations of $294.36 million.
TDOC presents a high-risk opportunity with significant upside potential given the $8.83 consensus price target, representing 59% upside. However, continued net losses, negative cash flow trends, and competitive pressures in telehealth create substantial execution risk. The stock's current valuation at 0.4x sales appears attractive if the company can achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
